Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus apatinib for refractory chordoma (phase II, single-arm)
ChiCTR2100042938Phase 2Recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Sep 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in chordoma, sponsored by Shanghai Changzheng Hospital. Primary endpoint: Objective Response Rate (ORR) by RECIST v1.1. Started Sep 2021; status: recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
chordoma
Beyond the preview
Go deeper on ChiCTR2100042938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100042938.